Press Releases Archives | Page 67 of 118

Invenra, Inc. Appoints Daniel S. Pereira, Ph.D., as Chief Scientific Officer

January 5, 2022 By Cade Hildreth, Founder & President Leave a Comment

Invenra builds out management team to advance immuno-oncology therapeutics pipeline and collaborative discovery efforts

MADISON, Wis., Jan 5, 2022 — Invenra, Inc., a biotechnology company focused on the discovery and development of multispecific antibodies for immuno-oncology, today announced the appointment of Daniel S. Pereira, Ph.D., as Chief Scientific Officer. Dr. Pereira brings more than 20 years of experience in oncology biologics drug discovery and development in biotech and pharma as a scientific leader, strategist, innovator, collaborator and fundraiser. His career efforts have led to the discovery and development of a range of FDA-approved drugs for patients with cancer. [Read more…]

BlueCube Bio Becomes Evia Bio™ and Launches iPSC Cryopreservation Solution for Cell & Gene Therapies

December 18, 2021 By Cade Hildreth, Founder & President Leave a Comment

BlueCube Bio officially announced a company name transition to EviaBio, conconcurrent with the launch of a significant new cryopreservation technology for use in cell and gene therapies utilizing Induced Pluripotent Stem Cells (iPSCs).

MINNEAPOLIS, Dec. 9, 2021 — BlueCube Bio officially announced a company name transition to Evia Bio™, concurrent with the launch of a significant new cryopreservation technology for use in cell and gene therapies utilizing Induced Pluripotent Stem Cells (iPSCs). The osmolyte-based solution increases cell survival above that of commercially available DMSO-based options which is critical for realizing the potential of these therapies. This latest addition expands the company’s portfolio of patented cryopreservation products that also include products for mesenchymal stem cells (MSCs). [Read more…]

AgeX Therapeutics’ Licensee ImStem Biotechnology Does First U.S. Multiple Sclerosis Patient with IMS001

December 15, 2021 By Cade Hildreth, Founder & President 1 Comment

ImStem’s MSC Product Candidate IMS001 is Derived from AgeX’s Pluripotent Stem Cell Line ESI-053.
IMS001 is an investigational, allogeneic, MSC product derived from a human embryonic stem cell line.
It is assumed to be the first hES-MSC based allogeneic cell therapy accepted for clinical trial by the FDA for patients with MS.

[Read more…]

denovoMATRIX releases isoMATRIX: Cell and Gene Therapy’s first high-yield MSC isolation technology

December 15, 2021 By Cade Hildreth, Founder & President Leave a Comment

DRESDEN, Germany, December 15, 2021 / BioInformant / — denovoMATRIX GmbH, an innovator in cell and gene therapy (CGT) manufacturing, announced the launch of a new technology for bringing down costs and increasing access to high-quality mesenchymal stromal cells (MSCs) for stem cell-based therapies. The technology termed isoMATRIX, is designed to isolate MSCs in xeno-/serum-free conditions with high efficiency and stemness enabling rapid cell expansion for radically reduced cost of goods (COGs) for cell therapy manufacturers.

[Read more…]

Winner of the European EIC Accelerator program, EVerZom accelerates the industrialization of its exosome bioproduction platform for regenerative medicine

December 1, 2021 By Cade Hildreth, Founder & President Leave a Comment

Paris, 18 November 2021 — EVerZom, a biopharmaceutical company specialized in the biomanufacturing of extracellular vesicles (or exosomes), announced today that it has obtained non-dilutive funding of €2.5 million as the winner of the European EIC Accelerator competition (Horizon Europe). This funding will enable the company to transfer its extracellular vesicle biomanufacturing technology for a first clinical grade batch production and to accelerate the scale-up of its production capabilities by developing a process compatible with clinical Phase 2/3 for the pharmaceutical industry. [Read more…]